Get the Stockscreener App
2.42
7.28%
-0.19
Insight Molecular Diagnostics Inc stock is traded at $2.42, with a volume of 3,652.
It is down -7.28% in the last 24 hours and up +0.00% over the past month.
Insight Molecular Diagnostics Inc is a pioneering diagnostics technology company whose mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes. The Company's flagship technology quantifies a molecular biomarker known as donor-derived cell-free DNA (dd-cfDNA). It is also in the process of rebranding its RUO test kit, GraftAssure, as GraftAssureIQ, and rebranding its future in-vitro diagnostic (IVD) test kit as GraftAssureDx.
See More
Previous Close:
$2.61
Open:
$2.45
24h Volume:
3,652
Relative Volume:
0.30
Market Cap:
$69.85M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-7.28%
1M Performance:
+0.00%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$2.4108
$2.4643
1-Week Range:
$2.4108
$2.73
52-Week Range:
$2.4108
$3.09
Insight Molecular Diagnostics Inc Stock (IMDX) Company Profile
Name
Insight Molecular Diagnostics Inc
Sector
Industry
Phone
949-409-7600
Address
15 CUSHING, IRVINE
Compare IMDX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMDX
Insight Molecular Diagnostics Inc
|
2.4422 | 73.50M | 0 | 0 | 0 | 0.00 |
|
TMO
Thermo Fisher Scientific Inc
|
466.58 | 173.97B | 43.21B | 6.58B | 6.17B | 17.29 |
|
DHR
Danaher Corp
|
201.26 | 143.61B | 24.01B | 3.41B | 4.86B | 4.70 |
|
IDXX
Idexx Laboratories Inc
|
652.83 | 52.65B | 4.04B | 985.66M | 774.34M | 12.01 |
|
A
Agilent Technologies Inc
|
114.92 | 32.56B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
181.99 | 30.58B | 15.50B | 1.33B | 2.16B | 7.34 |
Insight Molecular Diagnostics Inc Stock (IMDX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-28-25 | Initiated | Lake Street | Buy |
| May-24-22 | Downgrade | Stephens | Overweight → Equal-Weight |
| Mar-14-22 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| Jan-07-22 | Initiated | Stephens | Overweight |
| Jan-06-22 | Resumed | Piper Sandler | Overweight |
| Mar-17-21 | Resumed | Needham | Buy |
| Jan-07-21 | Upgrade | The Benchmark Company | Speculative Buy → Buy |
| Dec-16-20 | Upgrade | Piper Sandler | Neutral → Overweight |
| Nov-30-20 | Initiated | BTIG Research | Buy |
| Nov-10-20 | Initiated | KeyBanc Capital Markets | Overweight |
| Jul-30-20 | Reiterated | The Benchmark Company | Speculative Buy |
| Jul-01-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jun-30-20 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Jun-02-20 | Initiated | Needham | Buy |
| Feb-13-19 | Initiated | Piper Jaffray | Overweight |
| Jan-29-19 | Upgrade | Janney | Neutral → Buy |
| Dec-19-18 | Resumed | Lake Street | Buy |
View All
Insight Molecular Diagnostics Inc Stock (IMDX) Latest News
Needham reiterates Buy rating on Insight Molecular Diagnostics stock - Investing.com
Insight Molecular Diagnostics Reports Q2 2025 Progress - TipRanks
Insight Molecular Diagnostics: Q2 Earnings Snapshot - San Francisco Chronicle
Earnings call transcript: Insight Molecular Diagnostics Q2 2025 reveals strategic advancements - Investing.com
IMDX Reports Q2 2025 Results and Momentum Toward GraftAssureDx Launch - GlobeNewswire
IMDX Earnings: Major Breakthrough in $1B Transplant Testing Market as Mayo Clinic, Cleveland Clinic Join Trial - Stock Titan
Insight Molecular Diagnostics Inc expected to post a loss of 23 cents a shareEarnings Preview - TradingView
Insight Molecular Diagnostics Inc.Common Stock (Nasdaq:IMDX) Stock Quote - FinancialContent
Molecular Diagnostics Market Overview: Growth Factors to 2035 - MarketReports.us
PCR Molecular Diagnostics Market Global Forecast 2025–2032: Sector-Wise Insights - newstrail.com
Insight Molecular Diagnostics Inc. shares rise 8.81% premarket after QIAGEN's solid Q2 2025 results. - AInvest
iMDx to Release Second Quarter 2025 Results on August 11, 2025 and Attend Needham Virtual MedTech and Diagnostics Conference - The Manila Times
iMDx to Release Second Quarter 2025 Results on August 11, - GlobeNewswire
iMDx Announces Two Major Investor Events: Q2 Earnings and Needham Conference Back-to-Back - Stock Titan
Diagnostic Contract Manufacturing Market Forecast 2025–2034: Key Metrics and Strategic Insights - WhaTech
IMDX World Transplant Congress Late-Breaking Data - GlobeNewswire
IMDX World Transplant Congress Late-Breaking Data Potentially Sets New Bar for Predicting Graft Rejection in Kidney Transplant Patients - Yahoo Finance
U.S., Europe, and Asia Pacific Molecular Diagnostics Market - openPR.com
iMDx to Host Virtual KOL Event to Discuss its In-House - GlobeNewswire
Vanderbilt Professor Reveals Game-Changing In-House Kidney Transplant Testing Technology at Expert Event - Stock Titan
Analysts Are Bullish on Top Healthcare Stocks: ProMIS Neurosciences (PMN), Bruker (BRKR) - The Globe and Mail
Insight Molecular Diagnostics Inc. shares fall 3.16% intraday as ImmunoPrecise Antibodies Ltd. announces new findings. - AInvest
Insight Molecular Diagnostics Inc. shares rise 5.32% premarket after Seegene unveils new diagnostic system and data analytics platform. - AInvest
Insight Molecular Diagnostics Insiders Increase Holdings Amidst Bullish Bets - AInvest
Insight Molecular Diagnostics Insiders Placed Bullish Bets Worth US$2.82m - Yahoo Finance
U.S. In Vitro Diagnostics (IVD) Market and Competition - GlobeNewswire
U.S. In Vitro Diagnostics (IVD) Market and Competition Insights 2025-2034Next-Gen Genomic Tools and Decentralized Testing to Transform U.S. Diagnostics Landscape - Yahoo.co
Clinical Laboratory Services Market Expanding with Diagnostic Testing Growth and Automation Advancements - newstrail.com
Sepsis Diagnostics Market: Global Industry Overview, Trends, Challenges, and Regional Insights - PharmiWeb.com
Insight Molecular Diagnostics Inc. shares rise 1.24% intraday after Agilent Technologies and Oxford BioDynamics host webinar on 3D genomic biomarker discovery. - AInvest
Proteinase K Market Grows Amid Rising Demand for Molecular Research and Diagnostics - newstrail.com
Companion Diagnostic Technologies Market Watch: Strategic Forecasts Amid Rising Economic Volatility - newstrail.com
IVD Contract Manufacturing Services Market Watch: Strategic Forecasts Amid Rising Economic Volatility - newstrail.com
Molecular Diagnostics Market Future Business Opportunities 2025-2032 | USD 27.8 billion by 2032, CAGR of 9.1% - newstrail.com
3 Medical Info Systems Stocks to Buy Amid AI Boom and Tariff Risk - TradingView
Molecular Diagnostics Market Booming as Precision Medicine, - openPR.com
Liver Cancer Diagnostics Market Analysis 2025–2035 | Trends, Technologies & Regional Insights - PharmiWeb.com
Molecular Diagnostics Reagent Market Driven by Rising Infectious Diseases and Genetic Testing - openPR.com
Oncocyte Relocates HQ from Irvine to Nashville - Orange County Business Journal
Insight Molecular Diagnostics Approves Key Proposals at Annual Meeting - TipRanks
Seegene Launches STAgora™, a New Platform for Infectious Disease Analytics - PR Newswire
Insight Molecular Diagnostics Inc.(NasdaqCM:IMDX) dropped from Russell 3000E Growth Index - MarketScreener
Revolutionizing Healthcare: Molecular Diagnostics Market Set - openPR.com
What's Driving the Future of the Molecular Cytogenetics Market? - openPR.com
Early cancer detection company opening U.S. headquarters in Franklin - Nashville Post
Oncology Molecular Diagnostics Market in Flux: Recession Signals, Tariff Pressures & Strategic Forecasts - newstrail.com
We're Keeping An Eye On Insight Molecular Diagnostics' (NASDAQ:IMDX) Cash Burn Rate - Yahoo Finance
iMDx Reports Strong Head-to-Head Data in Kidney Transplant Rejection Testing - GlobeNewswire
Why Did Insight Molecular Plunge 12.28%? - AInvest
IMDXINSIGHT MOLECULAR DIAGNOSTICS INC Latest Stock News & Market Updates - Stock Titan
Insight Molecular Diagnostics Rebrands and Relocates Headquarters: A Strategic Pivot towards Transplant Medicine - AInvest
Insight Molecular Diagnostics Inc Stock (IMDX) Financials Data
There is no financial data for Insight Molecular Diagnostics Inc (IMDX). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
0.26%
0.54%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):